BiotechTube
Home/Pipeline/IV-administered oncology candidate

IV-administered oncology candidate

Oncology (unspecified)

Pre-clinical/Clinically ReadyActive

Key Facts

Indication
Oncology (unspecified)
Phase
Pre-clinical/Clinically Ready
Status
Active
Company
eTheRNA immunotherapies

About eTheRNA immunotherapies

eTheRNA immunotherapies is a platform-driven RNA-LNP technology company based in Niel, Belgium. It leverages decades of scientific expertise to offer integrated capabilities in RNA chemistry, LNP delivery technologies, and GMP manufacturing, supporting partners from discovery through clinical development. The company operates through a dual business model of technology/product partnering and is advancing its own clinical-stage pipeline, including an intratumoral oncology platform now in clinical testing with partner Almirall.

View full company profile

Therapeutic Areas

OncologyInfectious DiseasesImmunology

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a